---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004997"
form_type: "8-K"
ticker: null
cik: "0001621227"
company_name: "Adaptimmune Therapeutics PLC"
filed_at: "2024-04-12T23:59:59+00:00"
generated_at: "2026-06-03T23:24:21.714212+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adaptimmune-Genentech allogeneic T-cell collaboration terminated; focus on afami-cel PDUFA Aug 4

## Summary
- Genentech terminates 2021 collaboration on allogeneic T-cell therapies; termination effective ~Oct 7, 2024.
- Adaptimmune received $150M upfront and $35M milestones; no further milestones or payments due.
- Company reaffirms focus on afami-cel launch; PDUFA target date August 4, 2024; Investor Day April 18.
- Adaptimmune retains all rights to its iPSC-based allogeneic platform and autologous pipeline.

## SEC filing metadata
- accession: 0001558370-24-004997
- form_type: 8-K
- cik: 0001621227
- company_name: Adaptimmune Therapeutics PLC
- filed_at: 2024-04-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621227/000155837024004997/0001558370-24-004997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621227/000155837024004997/adap-20240410x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004997
- JSON: https://secwatch.observer/filing/0001558370-24-004997.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004997.txt

## Key facts
- Material Agreements
  Adaptimmune Therapeutics PLC terminated Strategic Collaboration and License Agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd. (effective 2024-04-10).
  - Action: termination
  - Agreement: collaboration
  - Counterparty: Genentech, Inc. and F. Hoffman-La Roche Ltd.
  - Effective: 2024-04-10
  source text: On April 10, 2024, Adaptimmune Limited, a wholly-owned subsidiary of Adaptimmune Therapeutics plc (“Adaptimmune”) received notice of termination of the Strategic Collaboration and License Agreement with Genentech, Inc. (“Genentech”) and F. Hoffman-La Roche Ltd. (the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621227/000155837024004997/0001558370-24-004997-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.